A5087538996- Pulmonary Hypertension Research and Treatments
- Cardiovascular Function and Risk Factors
- Venous Thromboembolism Diagnosis and Management
- Vascular Anomalies and Treatments
- Cardiovascular Issues in Pregnancy
- Heart Failure Treatment and Management
- Nuclear Issues and Defense
- Cardiac tumors and thrombi
- European history and politics
- Transplantation: Methods and Outcomes
- Cardiac Imaging and Diagnostics
- Cardiac Valve Diseases and Treatments
- Cardiovascular Effects of Exercise
- Congenital Heart Disease Studies
- Medical Imaging and Pathology Studies
- Mechanical Circulatory Support Devices
- German History and Society
- Twentieth Century Scientific Developments
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Liver Disease Diagnosis and Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Tracheal and airway disorders
- Cardiomyopathy and Myosin Studies
Kerckhoff Klinik
2016-2025
Justus-Liebig-Universität Gießen
2020-2022
Medical University of Vienna
2020
University of Tübingen
2018-2019
Molina Center for Energy and the Environment
2018
University of Veterinary Medicine Hannover, Foundation
2018
Universities of Giessen and Marburg Lung Center
2017
TransMIT (Germany)
2016
University of Bern
2009-2015
Thoracic Surgery Foundation
2015
Balloon pulmonary angioplasty (BPA) is an emerging treatment for patients with inoperable chronic thromboembolic hypertension (CTEPH). We report on a prospective series of 56 consecutive who underwent 266 BPA interventions (median, five per patient) at two German institutions. All comprehensive diagnostic work-up including right heart catheterisation baseline and 24 weeks after their last intervention. resulted in improvements WHO functional class, 6 min walk distance (mean change, +33 m),...
Aim of this prospective study was to evaluate the effects exercise training in patients with inoperable or residual chronic thromboembolic pulmonary hypertension (CTEPH).Thirty-five consecutive invasively confirmed CTEPH (16 women;19 men; mean age 61±15 years, artery pressure, 63±20 mmHg; primary n = 33, persisting after endarterectomy 2) on stable disease-targeted medication received in-hospital for 3 weeks and continued at home 15 weeks. Medication remained unchanged during period....
Pulmonary endarterectomy (PEA), pulmonary arterial hypertension (PAH) therapy and balloon angioplasty (BPA) are currently accepted therapies for chronic thromboembolic (CTEPH). This international CTEPH Registry identifies clinical characteristics of patients, diagnostic algorithms treatment decisions in a global context.1010 newly diagnosed consecutive patients were included the registry between February 2015 September 2016. Diagnosis was confirmed by right heart catheterisation,...
The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) is unknown. Previous studies from the United Kingdom and Spain have reported rates 1.75 0.9 per million, respectively. These figures, however, may underestimate true CTEPH. We prospectively enrolled patients newly diagnosed with CTEPH within 2016 in Germany. Data were obtained three German referral centers branch COMPERA, a European registry. was calculated based on population data, patient characteristics treatment...
Symptomatic patients with residual pulmonary perfusion defects or vascular lesions but no hypertension at rest are diagnosed chronic thromboembolic disease (CTED). Balloon angioplasty (BPA) is an emerging treatment for inoperable (CTEPH), data regarding the safety and efficacy of BPA in CTED lacking. We report a prospective series ten consecutive who underwent 35 interventions (median four per patient) two German institutions. All comprehensive diagnostic workup baseline 24 weeks after their...
Riociguat is the treatment of choice for inoperable patients with chronic thromboembolic pulmonary hypertension (CTEPH). We addressed here whether additional balloon angioplasty (BPA) provides further benefits. A prospective series 36 consecutive CTEPH were treated riociguat at least three months before BPA. All underwent diagnostic workup baseline, BPA treatments, and six after final intervention. The main outcome measures hemodynamic parameters World Health Organization (WHO) functional...
BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension (CTEPH) registry, conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on long-term survival patients with CTEPH. Since then, 2 additional treatments for inoperable CTEPH have become available: balloon angioplasty (BPA), an approved oral drug therapy guanylate cyclase stimulator riociguat. current registry aimed to evaluate effect these new therapeutic approaches in a worldwide...
Abstract Background The objective of this prospective study was to assess the prevalence anxiety and depression disorders their association with quality life (QoL), clinical parameters survival in patients pulmonary hypertension (PH). Methods We prospectively assessed 158 invasively diagnosed arterial (n = 138) inoperable chronic thromboembolic PH 20) by measures including (QoL, SF-36 questionnaire), cardiopulmonary exercise testing six minute walking distance questionnaires for (PHQ-9)...
Chronic thromboembolic pulmonary hypertension Diagnosis TreatmentIn the 2009 European Guidelines on diagnosis and treatment of (PH), one section covers aspects pathophysiology, chronic (CTEPH).The practical implementation guidelines for this disease is crucial importance, because CTEPH a subset PH which can potentially be cured by endarterectomy (PEA).Nowadays, commonly underdiagnosed not properly managed.Any patient with unexplained should evaluated presence CTEPH, ventilation/perfusion...
Symptomatic patients with chronic thromboembolic disease (CTED) without pulmonary hypertension often show an excessive increase in mean arterial pressure (MPAP) during exercise. We report on the impact of endarterectomy (PEA) haemodynamics a prospective series 32 consecutive CTED who underwent PEA. All had comprehensive diagnostic work-up including right heart catheterisation at baseline and 12 months after Furthermore, exercise was performed before After PEA, MPAP lower rest (20±3 versus...
Pulmonary endarterectomy (PEA) is the standard therapy for patients with chronic thromboembolic pulmonary hypertension (CTEPH). In immediate postoperative period, persistent increases risk of acute respiratory or right heart failure. arterial hypertension, prostanoid inhalation has been found to improve hemodynamics, ventricular function, gas exchange, and clinical outcome. We report results a double-blinded randomized trial aerosolized prostacyclin analogue iloprost in residual after...
Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by defective thrombus resolution, artery obstruction, and vasculopathy. TGFβ (transforming growth factor-β) signaling mutations have been implicated in arterial hypertension, whereas the role of pathophysiology CTEPH unknown.To determine whether endothelial cells contributes to nonresolution fibrosis.Venous thrombosis was induced inferior vena cava ligation mice with genetic deletion TGFβ1 platelets (Plt.TGFβ-KO) or type...
The aim of the study was to characterize RV adaptation varying loading conditions in patients with chronic thromboembolic hypertension (CTEPH) before and after pulmonary endarterectomy (PEA). Nearly 4% embolism develop CTEPH. PEA offers a cure excellent outcome. By use cardiovascular magnetic resonance (CMR) combined hemodynamic measurements arterial elastance (Ea-pulm_i), end-systolic right ventricular (Ees-RV_i) ventriculo-arterial coupling (Ea-pulm_i/Ees-RV_i) can be studied PEA....
The molecular mechanisms of progressive right heart failure are incompletely understood. In this study, we systematically examined transcriptomic changes occurring over months in isolated cardiomyocytes or whole tissues from failing and left ventricles rat models pulmonary artery banding (PAB) aortic (AOB). Detailed bioinformatics analyses resulted the identification gene signature, protein transcription factor networks specific to compensated decompensated disease states. Proteomic RNA-FISH...